Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CASM NYSE:CATX NYSE:INFU NYSE:NSPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCASMCAS Medical Systems$2.45$2.45$1.06▼$2.70$71.88M0.5179,750 shs64,728 shsCATXPerspective Therapeutics$3.68+1.4%$3.68$1.60▼$16.55$273.16M1.17952,907 shs371,049 shsINFUInfuSystem$8.83+17.4%$6.11$4.61▼$9.97$185.57M1.81157,035 shs654,482 shsNSPRInspireMD$2.42+1.3%$2.42$1.99▼$3.80$74.14M0.6103,289 shs49,023 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCASMCAS Medical Systems0.00%0.00%0.00%0.00%0.00%CATXPerspective Therapeutics+1.38%0.00%-2.65%+56.60%-68.30%INFUInfuSystem+17.42%+54.91%+40.38%+64.43%+27.97%NSPRInspireMD+1.26%-10.04%-0.41%-6.92%-15.38%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCASMCAS Medical SystemsN/AN/AN/AN/AN/AN/AN/AN/ACATXPerspective Therapeutics2.5259 of 5 stars4.61.00.00.02.60.80.0INFUInfuSystem3.1655 of 5 stars2.03.00.00.03.74.21.9NSPRInspireMD3.6412 of 5 stars3.53.00.00.03.94.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCASMCAS Medical Systems 0.00N/AN/AN/ACATXPerspective Therapeutics 3.18Buy$12.56241.18% UpsideINFUInfuSystem 4.00Strong Buy$12.5041.56% UpsideNSPRInspireMD 3.00Buy$4.5085.95% UpsideCurrent Analyst Ratings BreakdownLatest CASM, CATX, INFU, and NSPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.007/21/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy7/12/2025CATXPerspective TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.006/3/2025CATXPerspective TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.005/14/2025CATXPerspective TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $8.005/13/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$11.005/12/2025NSPRInspireMDPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$4.50 ➝ $4.00(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCASMCAS Medical Systems$21.92M3.28N/AN/A($0.56) per share-4.38CATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/AINFUInfuSystem$139.89M1.33$0.69 per share12.79$2.47 per share3.57NSPRInspireMD$7.07M10.49N/AN/A$1.83 per share1.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCASMCAS Medical Systems-$5.96M-$0.27N/AN/AN/A-27.26%N/A-50.97%N/ACATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%8/13/2025 (Estimated)INFUInfuSystem$870K$0.23147.1928.48N/A1.12%2.78%1.41%N/ANSPRInspireMD-$19.92M-$0.83N/AN/AN/A-413.96%-69.42%-57.68%N/ALatest CASM, CATX, INFU, and NSPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025N/ACATXPerspective Therapeutics-$0.30N/AN/AN/A$0.17 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCASMCAS Medical SystemsN/AN/AN/AN/AN/ACATXPerspective TherapeuticsN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ANSPRInspireMDN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCASMCAS Medical SystemsN/A2.332.04CATXPerspective TherapeuticsN/A9.609.60INFUInfuSystem0.501.981.59NSPRInspireMDN/A6.396.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCASMCAS Medical Systems27.61%CATXPerspective Therapeutics54.66%INFUInfuSystem71.13%NSPRInspireMD44.78%Insider OwnershipCompanyInsider OwnershipCASMCAS Medical Systems37.60%CATXPerspective Therapeutics3.72%INFUInfuSystem11.40%NSPRInspireMD34.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCASMCAS Medical Systems7629.34 millionN/ANot OptionableCATXPerspective Therapeutics7074.23 million65.21 millionOptionableINFUInfuSystem41021.02 million19.10 millionOptionableNSPRInspireMD5030.64 million18.33 millionOptionableCASM, CATX, INFU, and NSPR HeadlinesRecent News About These CompaniesInspireMD, Inc. (NASDAQ:NSPR) Q2 2025 Earnings Call TranscriptAugust 6 at 8:56 AM | msn.comInspireMD, Inc. (NSPR) Q2 2025 Earnings Call TranscriptAugust 6 at 2:08 AM | seekingalpha.comInspireMD Reports Second Quarter 2025 Financial ResultsAugust 5, 2025 | globenewswire.comInspireMD Q2 2025 Earnings PreviewAugust 4, 2025 | msn.comWhat to Expect from InspireMD Inc (NSPR) Q2 2025 EarningsAugust 4, 2025 | finance.yahoo.comInvestors in InspireMD (NASDAQ:NSPR) from five years ago are still down 60%, even after 11% gain this past weekAugust 3, 2025 | finance.yahoo.comInspireMD, Inc. (NYSE:NSPR) CEO Marvin Slosman Acquires 10,330 SharesAugust 2, 2025 | marketbeat.comInspireMD, Inc. (NYSE:NSPR) Director Paul Stuka Acquires 20,661 SharesAugust 2, 2025 | marketbeat.comThomas J. Kester Acquires 30,991 Shares of InspireMD, Inc. (NYSE:NSPR) StockAugust 2, 2025 | marketbeat.comInspireMD, Inc. (NYSE:NSPR) Director Acquires $99,999.24 in StockAugust 2, 2025 | marketbeat.comMarvin Slosman Acquires 10,330 Shares of InspireMD, Inc. (NYSE:NSPR) StockAugust 2, 2025 | insidertrades.comInspireMD brings in $58M, adds former Axonics CEO to boardJuly 31, 2025 | massdevice.comInspireMD Announces the Appointment of Raymond W. Cohen to its Board of DirectorsJuly 31, 2025 | globenewswire.comInspireMD Announces Combined Financings of $58 MillionJuly 31, 2025 | globenewswire.comInspireMD to Announce Second Quarter 2025 Financial ResultsJuly 22, 2025 | globenewswire.comInspireMD Launches CGuard Prime Carotid Stent System in the U.S.July 11, 2025 | zacks.comInspireMD’s CGuard Prime Carotid Stent System Launched in United StatesJuly 10, 2025 | evtoday.comEInspireMD stock rises after US commercial launch of carotid stent systemJuly 10, 2025 | au.investing.comInspireMD launches carotid stent in U.S. after FDA approvalJuly 10, 2025 | massdevice.comInspireMD Shares Rise on U.S. Rollout of CGuard Prime Carotid StentJuly 10, 2025 | msn.comInspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of StrokeJuly 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCASM, CATX, INFU, and NSPR Company DescriptionsCAS Medical Systems NASDAQ:CASMCAS Medical Systems, Inc., a medical technology company, develops, manufactures, and markets non-invasive patient monitoring products worldwide. The company provides FORE-SIGHT tissue oximeter monitors, sensors, and accessories, as well as offers FORE-SIGHT ELITE monitors. Its FORE-SIGHT absolute tissue oximeter provides non-invasive and quantitative measurement of oxygenation for cerebral tissue during surgery or critical care situations. The company also offers repair services for parts. It markets products through its own sales force, distributors, and manufacturers' representatives, as well as through hospitals, surgery centers, and outpatient facilities. CAS Medical Systems, Inc. was founded in 1984 and is headquartered in Branford, Connecticut.Perspective Therapeutics NYSE:CATX$3.68 +0.05 (+1.38%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$3.66 -0.03 (-0.68%) As of 08/8/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.InfuSystem NYSE:INFU$8.83 +1.31 (+17.42%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$9.16 +0.33 (+3.69%) As of 08/8/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.InspireMD NYSE:NSPR$2.42 +0.03 (+1.26%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$2.42 +0.00 (+0.21%) As of 08/8/2025 05:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down DraftKings Posts Record Quarter, Eyes Profitability Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
